Therapies for Pediatric Patients with Sickle Cell Disease

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: October 25, 2021
Expiration Date: October 25, 2022

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, two experts discuss the care of pediatric patients with sickle cell disease, including updated information on therapies. This activity will conclude with a review of the Florida-based quality improvement study, designed to improve quality of care for patients, and how to implement and monitor the standard of care. Don't miss the opportunity to participate in this QI program led by Dr. Bronté-Hall. Information on how you can participate will be provided at the end of the program. ​

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including primary care physicians, hematologists, oncologists, nurses and other allied healthcare professionals who provide care to patients with sickle cell disease.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Consider the incidence and burden of sickle cell disease in Florida and nationwide
  • Utilize appropriate therapy for the treatment and prevention of acute vaso-occlusive crisis in patients with sickle cell disease
  • Talk with patients and families about curative options for sickle cell disease
  • Institute a quality improvement project to address barriers to optimal care and improve outcomes for patients with sickle cell disease, in collaboration with The Sunshine Sickle Cell Project quality improvement initiative


Therapies for Pediatric Patients with Sickle Cell Disease - Andrew Campbell, MD
Sunshine Sickle Cell Project: A Quality Improvement Initiative - Lanetta Bronté-Hall, MD, MPH, MSPH

Instructions for Participation and Credit

This activity is eligible for credit through October 25, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Lanetta Bronté-Hall, MD, MPH, MSPH
Foundation for Sickle Cell Disease Research
Hollywood, Florida

Dr. Lanetta Bronté-Hall received a joint medical degree and master of public health with a specialization in health policy and administration from the University of North Carolina School of Medicine and Gillings School of Global Public Health. She completed an internship in internal medicine at Tulane University School of Medicine, and a residency in psychiatry at the University of Miami, Miller School of Medicine. In addition, she completed a health research and educational trust/American Hospital Association fellowship in cultural competence and leadership. Dr. Bronté-Hall is currently President and CEO of the Foundation for Sickle Cell Disease Research (FSCDR), where she is responsible for strategic planning, scientific, and administrative oversight. In addition, she is Chief Health Officer of the Sickle Care and Research Network, FSCDR, LLC, an independent full-service outpatient medical treatment and clinical trials center that offers medical and coordinated care for underserved populations. Dr. Bronté-Hall is also an Associate Professor in the Department of Public Health Sciences, Department of Health Services Research and Policy at the University of Miami’s Miller School of Medicine, where she has created a sickle cell disease research portfolio and an academic–community partnership to translate research into practice.

Dr. Bronté-Hall has served in several leadership positions including the Chief Medical Officer of the Sickle Cell Disease Association of America, Senior Medical Advisor to the Centers for Disease Prevention and Control, and as a member of the National Institutes of Health, National Heart, Lung and Blood Advisory Council. A leading national and international researcher and population health scientist in the field of sickle cell disease, rare blood disorders, community-based participatory research, and chronic disease management, Dr. Bronté-Hall has extensive experience in developing programs that are closely aligned with the recruitment and retention of underserved and underrepresented populations for treatment of sickle cell disease and breast cancer research and clinical trials. She has spearheaded a Sickle Cell Disease and Thalassemia Registry. Dr. Bronté-Hall works tirelessly to create an environment of trust, sustainability and relevance, which has significantly increased participation in research by all members of the community.

Andrew Campbell, MD
Associate Professor of Pediatrics
George Washington University School of Medicine
Director, Comprehensive Sickle Cell Program
Children’s National Medical Center
Washington, DC

Dr. Andrew Campbell received his medical degree from Case Western Reserve School of Medicine. He completed his pediatric residency program at Massachusetts General Hospital, and his pediatric hematology/oncology fellowship at Northwestern University. Dr. Campbell is an Associate Professor of Pediatrics at George Washington University School of Medicine in Washington, DC, and Director of the Comprehensive Sickle Cell Disease Program. He is Global Health Research Lead at Children’s National Hospital and has extensive global health research in sickle cell disease (SCD). As director of the international Consortium for the Advancement of Sickle Cell Disease Research (CASiRe), Dr. Campbell has focused his research in understanding the varied phenotypic expression of SCD in different populations.


MediCom Worldwide, Inc. CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MediCom Worldwide, Inc. NURSING CREDIT
is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-040-150


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. Lanetta Bronté-Hall has disclosed no relevant financial relationships.

Dr. Andrew Campbell has received honoraria as a consultant from bluebird bio, Inc., Global Blood Therapeutics, Inc., and Novartis AG. He has received grant support related to research activities from Global Blood Therapeutics and Novartis.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Novartis Pharmaceuticals.

©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203, Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.